Marksans Pharma receives USFDA approval for Benzonatate capsules

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners

Zydus receives USFDA approval for cevimeline hydrochloride capsules

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

Eugia Pharma launches Pomalidomide capsules in US market

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology

Iambic taps AI to power multi-year drug discovery deal with Takeda